Jun 17, 2026 04:15PM
Jun 11, 2026 04:15PM
Jun 2, 2026 07:05PM
Jun 2, 2026 07:05PM
May 28, 2026 07:05AM
May 19, 2026 07:05AM
May 19, 2026 07:05AM Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
May 18, 2026 04:15PM
May 13, 2026 06:50AM
May 13, 2026 06:50AM
May 13, 2026 06:00AM
Apr 17, 2026 04:15PM
Mar 27, 2026 12:13AM
Mar 27, 2026 12:12AM Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
Mar 26, 2026 04:01PM
Mar 26, 2026 04:01PM
Mar 16, 2026 06:01PM
Mar 16, 2026 07:00AM
Feb 20, 2026 04:15PM
Feb 9, 2026 07:05AM
Feb 9, 2026 07:05AM Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
Feb 4, 2026 07:05AM
Jan 16, 2026 04:15PM
Jan 5, 2026 07:05AM
Jan 5, 2026 07:05AM
Dec 19, 2025 04:15PM
Dec 15, 2025 07:05AM
Dec 15, 2025 07:05AM Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
Nov 12, 2025 07:05AM
Nov 11, 2025 07:05AM
Oct 27, 2025 07:05AM
Oct 27, 2025 07:05AM
Oct 8, 2025 05:00AM
Oct 8, 2025 05:00AM
Sep 2, 2025 07:15AM Royalty Pharma provides up to $300 million to Zenas BioPharma for obexelimab
Sep 2, 2025 07:15AM
Sep 2, 2025 07:05AM
Aug 26, 2025 07:05AM
Aug 12, 2025 07:05AM
Jun 20, 2025 04:15PM
May 29, 2025 07:05AM
May 15, 2025 07:05AM Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Apr 17, 2025 04:20PM
Apr 7, 2025 07:06AM
Apr 7, 2025 07:05AM
Mar 17, 2025 07:05AM
Mar 17, 2025 07:05AM
Feb 5, 2025 07:05AM
Jan 28, 2025 08:00AM Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
Nov 12, 2024 07:10AM

1,160,205 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All